9 hours ago · In this report, we have described a 50-year-old male patient with hepatocellular carcinoma had nasopharynx metastases two months after his initial diagnosis and interventional treatment, indicating that though nasopharynx metastasis of the hepatocellular carcinoma is relatively low, it really occurs. >> Go To The Portal
A case of a 62-year-old patient with hereditary hemochromatosis is reported, who developed hepatocellular carcinoma (HCC
The most common form of liver cancer often seen in people with chronic liver diseases like cirrhosis.
A degenerative disease of the liver resulting in scarring and liver failure.
Full Answer
Amador A, Monforte NG, Bejaran ON, Martí J, Artigau E, Navarro S, Fuster J. Cutaneous metastasis from hepatocellular carcinoma as the first clinical sign. J Hepatobiliary Pancreat Surg. 2007;14:328–330.
Sarcomatoid hepatocellular carcinoma (SHC) is a rare malignant hepatic tumor. Recurrent interventional therapies such as transcatheter arterial chemo-embolization (TACE), radiofrequency ablation (RFA), and percutaneous ethanol injection have been reported previously utilized in a majority of SHC cases.
Sarcomatoid hepatocellular carcinoma (SHC) is a rare neoplasm of the liver, accounting for 1.8–2.0% of all patients undergoing surgery [ 4, 5 ]. The diagnosis of SHC requires postoperative pathological examination, while the preferred therapy is surgical excision. The prognosis of SHC remains very poor due to frequent recurrence and metastasis.
This case report is important because we demonstrate a unique presentation of hepatocellular carcinoma (HCC) with metastases to the gingiva and likely the penis. A review of the literature demonstrates the rarity of this presentation.
Although liver cancer can happen at any age, it is most common in older people. Most people diagnosed are over the age of 60. The highest rates are in 85 to 89 year olds.
Major risk factors for HCC include chronic alcohol consumption, hepatitis B, hepatitis C and non-alcoholic fatty liver disease [3]. Other, less common causes are Wilson's disease, hereditary hemochromatosis, alpha1-antitrypsin deficiency, primary biliary cirrhosis and autoimmune hepatitis [4, 5].
The current treatments for HCC with established efficacy include: (1) surgical resection (SR)/liver transplantation (LT); (2) transcatheter arterial chemoembolization (TACE); (3) percutaneous radiofrequency ablation (RFA); (4) percutaneous ethanol injection (PEI); (5) percutaneous microwave coagulation therapy (PMCT); ...
Hepatocellular carcinoma (HCC) is a complex disease and a major cause of death in high endemic areas of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. HCC has gone from being a universal death sentence to a cancer that can be prevented, detected at an early stage and effectively treated.
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection.
No. However, one of the risk factors for developing hepatocellular carcinoma is hereditary hemochromatosis, which does have a genetic association. Liver tumors may be primary (originating from the liver) or metastatic (spread from a cancer elsewhere).
The overall median survival of the TACE group (8.0 months) was significantly longer than that of the non-TACE (2.0 months; P ≤ . 01). Of the patients at BCLC-C and Child-Pugh-B, the overall median survivals of the TACE and non-TACE patients were 6.0 and 2.0 months, respectively (P ≤ .
If caught early, it can sometimes be cured with surgery or transplant. In more advanced cases it can't be cured, but treatment and support can help you live longer and better.
Without treatment, the median survival for stage A liver cancer is 3 years. With treatment, between 50 and 70 out of 100 people (between 50 – 70%) will survive for 5 years or more.
The estimated time needed for a HCC to grow from 1 cm to 2 cm was 212 days in patients with HBV infection and 328 days in those with HCV infection.
The immediate cause of death was tumor progression in 40 patients; cirrhosis complications in 23 patients; treatment related complications in 6 and infectious complications in 14. Tumor related deaths were as follows: BCLC A 7 deaths; BCLC B 6 deaths, BCLC C 26 deaths and BCLC D 18 deaths.
Hepatocelluar carcinoma, a type of liver cancer, is deadly. Even in the best-case scenario -- a localized tumor detected before it spreads from the liver -- the five-year survival rate is only 33 percent.